INDSWFTLAB
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Ind Swift Laboratories Ltd - Approves Short-Term Advance Of Up To 200 Million Rupees
IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD - APPROVES SHORT-TERM ADVANCE OF UP TO 200 MILLION RUPEES
Source text: ID:nBSEbdl2jw
Further company coverage: ISLB.NS
IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD - APPROVES SHORT-TERM ADVANCE OF UP TO 200 MILLION RUPEES
Source text: ID:nBSEbdl2jw
Further company coverage: ISLB.NS
Ind Swift Laboratories Completes Land Purchase For 177.2 Million Rupees
Jan 1 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD -COMPLETES LAND PURCHASE FOR 177.2 MILLION RUPEES
Source text: ID:nNSE1pzGDw
Further company coverage: ISLB.NS
(([email protected];))
Jan 1 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD -COMPLETES LAND PURCHASE FOR 177.2 MILLION RUPEES
Source text: ID:nNSE1pzGDw
Further company coverage: ISLB.NS
(([email protected];))
Ind Swift Laboratories Approved Preferential Issue Of Up To 26 Million Warrants
June 27 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED PREFERENTIAL ISSUE OF UP TO 26 MILLION WARRANTS TO PROMOTER & PROMOTER GROUP AND NONPROMOTER CATEGORY
Further company coverage: ISLB.NS
(([email protected];))
June 27 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED PREFERENTIAL ISSUE OF UP TO 26 MILLION WARRANTS TO PROMOTER & PROMOTER GROUP AND NONPROMOTER CATEGORY
Further company coverage: ISLB.NS
(([email protected];))
Ind Swift Laboratories To Consider Raising Of Funds
June 24 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
TO CONSIDER AND APPROVE PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE8MZLxR
Further company coverage: ISLB.NS
(([email protected];;))
June 24 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
TO CONSIDER AND APPROVE PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE8MZLxR
Further company coverage: ISLB.NS
(([email protected];;))
India's Ind-Swift Labs up after March-quarter profit
** Shares of Ind-Swift Laboratories ISLB.NS up 10.8% to 116.6 rupees
** Formulations maker posted March-quarter consolidated net profit from loss a year earlier
** Stock on track for best day since April 5
** YTD, stock up 12.6%
(Reporting by Varun Vyas in Bengaluru)
** Shares of Ind-Swift Laboratories ISLB.NS up 10.8% to 116.6 rupees
** Formulations maker posted March-quarter consolidated net profit from loss a year earlier
** Stock on track for best day since April 5
** YTD, stock up 12.6%
(Reporting by Varun Vyas in Bengaluru)
Ind Swift Laboratories Posts March-Quarter Consol Net PAT At 2.39 Bln Rupees
May 13 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES MARCH-QUARTER CONSOL NET PAT 2.39 BILLION RUPEES VERSUS LOSS 251.2 MILLION RUPEES
IND SWIFT LABORATORIES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.93 BILLION RUPEES VERSUS 3.04 BILLION RUPEES
Source text for Eikon: ID:nBSE3MjntR
Further company coverage: ISLB.NS
(([email protected];))
May 13 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES MARCH-QUARTER CONSOL NET PAT 2.39 BILLION RUPEES VERSUS LOSS 251.2 MILLION RUPEES
IND SWIFT LABORATORIES MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.93 BILLION RUPEES VERSUS 3.04 BILLION RUPEES
Source text for Eikon: ID:nBSE3MjntR
Further company coverage: ISLB.NS
(([email protected];))
IND Swift Laboratories Approves Incorporation Of Unit In Dubai
April 19 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED INCORPORATION OF UNIT IN DUBAI, UNITED ARAB EMIRATES
Source text for Eikon: ID:nBSE8hXp61
Further company coverage: ISLB.NS
(([email protected];))
April 19 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED INCORPORATION OF UNIT IN DUBAI, UNITED ARAB EMIRATES
Source text for Eikon: ID:nBSE8hXp61
Further company coverage: ISLB.NS
(([email protected];))
Ind Swift Approves Modifications In Merger Of Co With Ind Swift Laboratories
March 8 (Reuters) - Ind Swift Ltd INSW.NS:
APPROVED MODIFICATIONS IN SCHEME OF ARRANGEMENT FOR AMALGAMATION OF CO WITH IND SWIFT LABORATORIES
Source text for Eikon: ID:nBSE3lXVml
Further company coverage: INSW.NS
(([email protected];))
March 8 (Reuters) - Ind Swift Ltd INSW.NS:
APPROVED MODIFICATIONS IN SCHEME OF ARRANGEMENT FOR AMALGAMATION OF CO WITH IND SWIFT LABORATORIES
Source text for Eikon: ID:nBSE3lXVml
Further company coverage: INSW.NS
(([email protected];))
Ind Swift Laboratories Amends Terms Of Agreement With Synthimed
March 5 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD- APPROVING INVESTMENT OF 320 MILLION RUPEES TOWARDS SERIES A COMPULSORILY CONVERTIBLE DEBENTURES
IND SWIFT LABORATORIES LTD - APPROVED AMENDMENT TO TERMS OF AGREEMENT EXECUTED BY COMPANY AND SYNTHIMED
IND SWIFT LABORATORIES LTD- APPROVED INVESTMENT IN CCDS OF SYNTHIMED INSTEAD OF SHARES, CCPS
Source text for Eikon: ID:nBSE389qbM
Further company coverage: ISLB.NS
(([email protected];))
March 5 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
IND SWIFT LABORATORIES LTD- APPROVING INVESTMENT OF 320 MILLION RUPEES TOWARDS SERIES A COMPULSORILY CONVERTIBLE DEBENTURES
IND SWIFT LABORATORIES LTD - APPROVED AMENDMENT TO TERMS OF AGREEMENT EXECUTED BY COMPANY AND SYNTHIMED
IND SWIFT LABORATORIES LTD- APPROVED INVESTMENT IN CCDS OF SYNTHIMED INSTEAD OF SHARES, CCPS
Source text for Eikon: ID:nBSE389qbM
Further company coverage: ISLB.NS
(([email protected];))
Cci Approves Proposed Acquisition Of Certain Business Undertakings Of Ind Swift Laboratories Ltd And Essix Biosciences Lid By Synthimed Labs Pvt Ltd - Government Statement
IND Swift Laboratories Ltd ISLB.NS:
CCI APPROVES PROPOSED ACQUISITION OF CERTAIN BUSINESS UNDERTAKINGS OF IND SWIFT LABORATORIES LTD AND ESSIX BIOSCIENCES LID BY SYNTHIMED LABS PVT LTD - GOVERNMENT STATEMENT
Source text for Eikon: [ID:]
Further company coverage: ISLB.NS
IND Swift Laboratories Ltd ISLB.NS:
CCI APPROVES PROPOSED ACQUISITION OF CERTAIN BUSINESS UNDERTAKINGS OF IND SWIFT LABORATORIES LTD AND ESSIX BIOSCIENCES LID BY SYNTHIMED LABS PVT LTD - GOVERNMENT STATEMENT
Source text for Eikon: [ID:]
Further company coverage: ISLB.NS
Ind Swift Laboratories Collaborates With Csir-Imtech
Nov 29 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
COLLABORATES WITH CSIR-IMTECH
Source text for Eikon: ID:nBSE3MVkgT
Further company coverage: ISLB.NS
(([email protected];;))
Nov 29 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
COLLABORATES WITH CSIR-IMTECH
Source text for Eikon: ID:nBSE3MVkgT
Further company coverage: ISLB.NS
(([email protected];;))
Ind Swift Laboratories Approved Scheme Of Arrangement Of Ind Swift With Ind Swift Laboratories On A Going Concern Basis
Sept 25 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED SCHEME OF ARRANGEMENT OF IND SWIFT WITH IND SWIFT LABORATORIES ON A GOING CONCERN BASIS
Source text for Eikon: ID:nBSE2z5szB
Further company coverage: ISLB.NS
(([email protected];;))
Sept 25 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED SCHEME OF ARRANGEMENT OF IND SWIFT WITH IND SWIFT LABORATORIES ON A GOING CONCERN BASIS
Source text for Eikon: ID:nBSE2z5szB
Further company coverage: ISLB.NS
(([email protected];;))
India's Ind-Swift Labs to sell pharma ingredients ops for $198.5 mln
BENGALURU, Sept 6 (Reuters) - India's Ind-Swift Laboratories ISLB.NS said on Wednesday it would sell its active pharmaceuticals ingredients (API) and contract research and manufacturing services (CRAMS) business to Synthimed Labs in a deal with an enterprise value of 16.50 billion rupees ($198.50 million).
($1 = 83.1238 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru; Editing by Savio D'Souza)
(([email protected]; +91 7982114624;))
BENGALURU, Sept 6 (Reuters) - India's Ind-Swift Laboratories ISLB.NS said on Wednesday it would sell its active pharmaceuticals ingredients (API) and contract research and manufacturing services (CRAMS) business to Synthimed Labs in a deal with an enterprise value of 16.50 billion rupees ($198.50 million).
($1 = 83.1238 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru; Editing by Savio D'Souza)
(([email protected]; +91 7982114624;))
Ind Swift Laboratories Approves Sale Of Property Of Co At Mumbai At Total Consideration Of 27.5 Million Rupees
Aug 31 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED SALE OF PROPERTY OF CO AT MUMBAI AT TOTAL CONSIDERATION OF 27.5 MILLION RUPEES
Source text for Eikon: ID:nBSE7788L9
Further company coverage: ISLB.NS
(([email protected];;))
Aug 31 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
APPROVED SALE OF PROPERTY OF CO AT MUMBAI AT TOTAL CONSIDERATION OF 27.5 MILLION RUPEES
Source text for Eikon: ID:nBSE7788L9
Further company coverage: ISLB.NS
(([email protected];;))
India's Ind Swift Laboratories June-Quarter Consol Net PAT Falls
Aug 9 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
JUNE-QUARTER CONSOL NET PAT 172.4 MILLION RUPEES VERSUS PROFIT 198.8 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.1 BILLION RUPEES VERSUS 2.8 BILLION RUPEES
Source text for Eikon: ID:nBSE1hLKd4
Further company coverage: ISLB.NS
(([email protected];;))
Aug 9 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
JUNE-QUARTER CONSOL NET PAT 172.4 MILLION RUPEES VERSUS PROFIT 198.8 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.1 BILLION RUPEES VERSUS 2.8 BILLION RUPEES
Source text for Eikon: ID:nBSE1hLKd4
Further company coverage: ISLB.NS
(([email protected];;))
India's Ind Swift Laboratories March-Quarter Consol Net Loss After Tax Narrows
May 29 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
MARCH-QUARTER CONSOL NET LOSS AFTER TAX 240.8 MILLION RUPEES VERSUS LOSS 614.5 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.04 BILLION RUPEES VERSUS 3.07 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: ISLB.NS
(([email protected];;))
May 29 (Reuters) - IND Swift Laboratories Ltd ISLB.NS:
MARCH-QUARTER CONSOL NET LOSS AFTER TAX 240.8 MILLION RUPEES VERSUS LOSS 614.5 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.04 BILLION RUPEES VERSUS 3.07 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: ISLB.NS
(([email protected];;))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Ind-Swift Lab. do?
Ind-Swift Laboratories Ltd, based in Chandigarh, India, is a global manufacturer of APIs, Intermediates, and formulations. Established in 1995, the company focuses on API manufacturing and is a key player in the Indian pharmaceutical industry.
Who are the competitors of Ind-Swift Lab.?
Ind-Swift Lab. major competitors are Venus Remedies, Sakar Healthcare, Lincoln Pharma, Wanbury, Fredun Pharma, Jagsonpal Pharma, Anuh Pharma. Market Cap of Ind-Swift Lab. is ₹999 Crs. While the median market cap of its peers are ₹923 Crs.
Is Ind-Swift Lab. financially stable compared to its competitors?
Ind-Swift Lab. seems to be less financially stable compared to its competitors. Altman Z score of Ind-Swift Lab. is 4.63 and is ranked 6 out of its 8 competitors.
Does Ind-Swift Lab. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Ind-Swift Lab. latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Ind-Swift Lab. allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory
How strong is Ind-Swift Lab. balance sheet?
Balance sheet of Ind-Swift Lab. is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Ind-Swift Lab. improving?
No, profit is decreasing. The profit of Ind-Swift Lab. is ₹248 Crs for TTM, ₹250 Crs for Mar 2025 and ₹421 Crs for Mar 2024.
Is the debt of Ind-Swift Lab. increasing or decreasing?
Yes, The net debt of Ind-Swift Lab. is increasing. Latest net debt of Ind-Swift Lab. is -₹378.1 Crs as of Sep-25. This is greater than Mar-25 when it was -₹821.6 Crs.
Is Ind-Swift Lab. stock expensive?
Ind-Swift Lab. is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Ind-Swift Lab. is 4.32, while 3 year average PE is 8.19. Also latest EV/EBITDA of Ind-Swift Lab. is 12444 while 3yr average is 60.84.
Has the share price of Ind-Swift Lab. grown faster than its competition?
Ind-Swift Lab. has given lower returns compared to its competitors. Ind-Swift Lab. has grown at ~15.37% over the last 9yrs while peers have grown at a median rate of 24.26%
Is the promoter bullish about Ind-Swift Lab.?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Ind-Swift Lab. is 39.5% and last quarter promoter holding is 39.5%.
Are mutual funds buying/selling Ind-Swift Lab.?
There is Insufficient data to gauge this.
